Figure 5 | Scientific Reports

Figure 5

From: Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

Figure 5

Mutant ER Results in Loss of Synergism Between Tamoxifen and PI3K Inhibitor. Y537S mutant was transfected into MCF-7 (MCF-7/Y537S) or ZR 75-1 (ZR75-1/Y537S) by lipofectamine 2000. Combination indices for T + BYL in (A) MCF-7, (B) MCF-7/Y537S, (E) ZR 75-1, (F) ZR 75-1/Y537S or tamoxifen(T) + buparisib(BKM), in (C) MCF-7, (D) MCF-7/Y537S, (G) ZR 75-1, (H) ZR 75-1/Y537S after 72 hours of treatment.

Back to article page